

Please type a plus sign (+) inside this box → +

11

Substitute for FORM 1449A/B/PTO		<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number:	10/567766
		Filing Date:	February 10, 2006
		First Named Inventor:	HASEGAWA, Hideki
		Group Art Unit:	1642
		Confirmation Number:	5560
		Examiner Name:	
(Use as many sheets as necessary)			
Sheet 1 of 1		Attorney Docket Number: 43512-103808	

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	B G	Harandi et al., "Recent developments in mucosal immunomodulatory adjuvants," <i>Cur. Opn. Investigational Drugs</i> , 4(2): 156-161 (2003).		
	B H	Holmgren et al, "Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA." <i>Expert Rev. of Vaccines</i> , 2(2): 205-217 (2003).		
	B I	Jiang et al., "Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NF $\kappa$ B and MAP kinase is through an interleukin-1 receptor-associate kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR," <i>J. Bio. Chem.</i> , 278(25): 16713-16719 (2003).		
	B J	Maeyama et al. "Effects of Recombinant Cholera Toxin B Subunit on IL-1 $\beta$ Production by Macrophages <i>In Vitro</i> ," <i>Microbiol. Immunol.</i> , 46(9): 593-599 (2002).		
	B K	Tamura, "Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza hemagglutinin vaccine," <i>Eur. J. Immunol.</i> , 22(2): 477-481 (1992).		
	B L	Wong et al., "Prophylactic and Therapeutic Efficacies of Poly (IC-LC) against Respiratory Influenza A virus Infection in Mice," <i>Antimicro. Agents and Chemotherapy</i> , 39(11): 2574-2576 (1995).		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /AB/

CHRS01.S0EVALIAS.4b3678x1

EXAMINER /Agnieszka Boesen/ DATE CONSIDERED 05/10/2009

<sup>4</sup> A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3)